Susquehanna International Group, LLP Kala Pharmaceuticals, Inc. Call Options Transaction History

Susquehanna International Group, LLP

15 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$0.3 - $1.31 $1,530 - $6,681	-5,100 Reduced 25.25%	15,100 $5,000
Q1 2022 May 16, 2022	SELL	$0.61 - $1.84 $61 - $184	-100 Reduced 0.49%	20,200 $28,000
Q3 2021 Nov 15, 2021	SELL	$2.62 - $5.43 $248,376 - $514,764	-94,800 Reduced 82.36%	20,300 $53,000
Q2 2021 Aug 11, 2021	BUY	$5.06 - $8.15 $475,133 - $765,285	93,900 Added 442.92%	115,100 $610,000
Q1 2021 May 17, 2021	SELL	$6.24 - $9.58 $570,960 - $876,570	-91,500 Reduced 81.19%	21,200 $143,000
Q4 2020 Feb 16, 2021	BUY	$6.28 - $8.79 $486,072 - $680,345	77,400 Added 219.26%	112,700 $764,000
Q2 2020 Aug 14, 2020	SELL	$8.33 - $13.79 $2.46 Million - $4.08 Million	-295,600 Reduced 89.33%	35,300 $371,000
Q1 2020 May 15, 2020	BUY	$3.83 - $8.79 $1.01 Million - $2.32 Million	263,700 Added 392.41%	330,900 $2.91 Million
Q4 2019 Feb 14, 2020	BUY	$3.36 - $4.81 $164,304 - $235,208	48,900 Added 267.21%	67,200 $248,000
Q3 2019 Nov 14, 2019	BUY	$3.57 - $6.58 $65,331 - $120,414	18,300 New	18,300 $70,000
Q1 2019 May 15, 2019	SELL	$5.19 - $8.97 $489,417 - $845,871	-94,300 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$4.29 - $9.94 $233,376 - $540,736	54,400 Added 136.34%	94,300 $461,000
Q3 2018 Nov 14, 2018	SELL	$9.54 - $13.87 $313,866 - $456,323	-32,900 Reduced 45.19%	39,900 $394,000
Q2 2018 Aug 14, 2018	BUY	$13.3 - $17.49 $254,030 - $334,058	19,100 Added 35.57%	72,800 $1 Million
Q1 2018 May 15, 2018	BUY	$12.26 - $18.98 $658,362 - $1.02 Million	53,700 New	53,700 $850,000

Ticker KALA
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 1,464,160
Market Cap $9.08M
Description
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.